Subscribe to RSS
DOI: 10.1055/s-0029-1225313
© Georg Thieme Verlag KG Stuttgart · New York
Update: Präklinische Entwicklungen zur Therapie der pulmonalen arteriellen Hypertonie
Update: Preclinical developments of the treatment of pulmonary arterial hypertensionPublication History
eingereicht: 6.5.2009
akzeptiert: 14.5.2009
Publication Date:
28 August 2009 (online)

Zusammenfassung
Die pulmonale arterielle Hypertonie (PAH) wird derzeit mit Substanzen behandelt, die primär eine Wiederherstellung der Balance des pulmonalvaskulären Tonus bewirken – namentlich die Prostanoide, Antagonisten des Endothelinrezeptors und die PDE-5-Inhibitoren – auch wenn diese Substanzen auch antiproliferative Effekte besitzen. Andere Substanzen, die direkt das Remodeling der Pulmonalarterien adressieren, werden derzeit nicht nur in präklinischen Tiermodellen, sondern auch bereits in klinischen Studien untersucht. Der Fokus der Grundlagenforschung liegt dabei sowohl auf der Ebene von Mediatoren und Rezeptoren, auf der Ebene von intrazellulären Signaltransduktionswegen und Transkriptionsfaktoren, sowie auf der Ebene der Effektoren.
Summary
Pulmonary arterial hypertension is a life-threatening, vasculoproliferative disease of the lung, which is characterized by vasoconstriction and remodeling of small pulmonary arteries. Drugs for the treatment of PAH mainly address the increased vascular tone. Substances like prostacyclin, endothelin-receptor-antagonists and phosphodiesterase-5-inhibitors have been approved for the treatment of PAH and represent the current therapeutic options. The development of a causal treatment aiming a normalization of the vessel wall structure is the current focus of research. The key events in disease progression are represented by increased proliferation, migration and a resistance to apoptosis of pulmonary vascular cells. Therefore, new non-vasoactive drugs are investigated in relevant preclinical animal models of pulmonary arterial hypertension. Some of these substances, like tyrosine kinase inhibitors, elastase inhibitors and phosphodiesterase-1-inhibitors, could not only attenuate (anti-remodeling) but reverse (reverse-remodeling) the disease. Additionally, new vasodilators, like soluble guanylate cyclase stimulators and activators, addressing well-known and new signaling pathways are currently under investigation. Taken together, with increasing insight into the pathology of PAH, several novel drug targets and treatments have emerged which may improve the management of patients and which efficacy is currently addressed in preclinical studies and clinical trials.
Schlüsselwörter
pulmonale arterielle Hypertonie - Gefäßremodeling - Vasokonstriktion
Keywords
pulmonary arterial hypertension - vascular remodeling - vasoconstriction
Literatur
- 1
Abe K, Shimokawa H, Morikawa K. et al .
Long-term treatment with a Rho-kinase inhibitor
improves monocrotaline-induced fatal pulmonary hypertension in rats.
Circ Res.
2004;
94
385-393
MissingFormLabel
- 2
Cowan K, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M.
Complete reversal of fatal pulmonary hypertension
in rats by a serine elastase inhibitor.
Nat Med.
2000;
6
698-702
MissingFormLabel
- 3
Dumitrascu R, Weissmann N, Ghofrani H A. et al .
Activation of soluble guanylate
cyclase reverses experimental pulmonary hypertension and vascular
remodeling.
Circulation.
2006;
113
286-295
MissingFormLabel
- 4
Ghofrani H A, Seeger W, Grimminger F.
Imatinib for the treatment of pulmonary
arterial hypertension.
N Engl J Med.
2005;
353
1412-1413
MissingFormLabel
- 5
Girgis R E, Mozammel S, Champion H C. et al .
Regression of chronic hypoxic pulmonary
hypertension by simvastatin.
Am J Physiol Lung Cell Mol
Physiol.
2007;
292
L1105-1110
MissingFormLabel
- 6
Guignabert C. et al .
Serotonin transporter inhibition prevents
and reverses monocrotaline-induced pulmonary hypertension in rats.
Circulation.
2005;
111
2812-2819
MissingFormLabel
- 7
Ishikura K, Yamada N, Ito M. et
al .
Beneficial acute effects of Rho-kinase inhibitor
in patients with pulmonary arterial hypertension.
Circ J.
2006;
70
174-178
MissingFormLabel
- 8
Kao P N.
Simvastatin treatment of pulmonary hypertension: an observational
case series.
Chest.
2005;
127
1446-1452
MissingFormLabel
- 9
Klein M, Schermuly R T, Ellinghaus P. et al .
Combined tyrosine and serine/threonine
kinase inhibition by sorafenib prevents progression of experimental
pulmonary hypertension and myocardial remodeling.
Circulation.
2008;
118
2081-2090
MissingFormLabel
- 10
Mittal M, Roth M, König P. et al .
Hypoxia-dependent regulation of nonphagocytic
NADPH oxidase subunit NOX4 in the pulmonary vasculature.
Circ
Res.
2007;
101
258-267
MissingFormLabel
- 11
Murray F, Patel H H, Suda R Y. et al .
Expression and activity
of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells
from patients with pulmonary hypertension: role for PDE 1.
Am J
Physiol Lung Cell Mol Physiol.
2007;
292
L294-L303
MissingFormLabel
- 12
Patterson K C, Weissmann A, Ahmadi T, Farber H W.
Imatinib
mesylate in the treatment of refractory idiopathic pulmonary arterial
hypertension.
Ann Intern Med.
2006;
145
152-153
MissingFormLabel
- 13
Rabinovitch M.
Elstase and the pathobiology of unexplained pulmonary hypertension.
Chest.
1998;
114 (3 Suppl.)
213S-224S
MissingFormLabel
- 14
Schermuly R T, Dony E, Ghofrani H A. et al .
Reversal of experimental pulmonary
hypertension by PDGF inhibition.
J Clin Invest.
2005;
115
2811-2821
MissingFormLabel
- 15
Schermuly R T, Pullamsetti S S, Kwapiszeswka G. et al .
Phosphodiesterase
1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling
therapy.
Circulation.
2007;
115
2331-2339
MissingFormLabel
- 16
Schermuly R T, Stasch J P, Pullamsetti P A. et al .
Expression and
function of soluble guanylate cyclase in pulmonary arterial hypertension.
Eur Respir J.
2008;
32
881-891
MissingFormLabel
- 17
Souza R, Sitbon O, Parent F, Simonneau G, Humbert M.
Long term imatinib treatment in pulmonary arterial hypertension.
Thorax.
2006;
61
736
MissingFormLabel
Prof. Dr. Ralph Schermuly
Max-Planck-Institut für Herz- und
Lungenforschung
Parkstraße 1
61231
Bad Nauheim
Phone: 06032/705380
Email: ralph.schermuly@mpi-bn.mpg.de